Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice

ConclusionChemoimmunotherapy with rituximab is feasible and safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities (ClinicalTrials. gov NCT01178086).This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Tags: Original Article Source Type: research